Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy

被引：0
|
作者：
Taiki Hakozaki
Yukio Hosomi
Akihiro Shimizu
Rui Kitadai
Kie Mirokuji
Yusuke Okuma
机构：
[1] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Department of Thoracic Oncology and Respiratory Medicine
[2] National Cancer Center Hospital,Department of Thoracic Oncology
来源：
Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷
关键词：
Polypharmacy; Non-small cell lung cancer; Overall survival; Geriatric oncology; Comorbidity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2659 / 2668
页数：9
相关论文
共 50 条
  • [31] MeImmS: Predict Clinical Benefit of Anti-PD-1/PD-L1 Treatments Based on DNA Methylation in Non-small Cell Lung Cancer
    Shang, Shipeng
    Li, Xin
    Gao, Yue
    Guo, Shuang
    Sun, Dailin
    Zhou, Hanxiao
    Sun, Yue
    Wang, Peng
    Zhi, Hui
    Bai, Jing
    Ning, Shangwei
    Li, Xia
    FRONTIERS IN GENETICS, 2021, 12
  • [32] PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions
    Xia, Liliang
    Liu, Yuanyong
    Wang, Ying
    ONCOLOGIST, 2019, 24 : S31 - S41
  • [33] Prognostic role of neutrophil/lymphocyte ratio (NLR) in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: a meta-analysis
    Zhang, Yu
    Wang, Wei
    LYu, Lan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 13 (12): : 9194 - 9206
  • [34] Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 Expression
    Hendriks, Lizza E. L.
    Remon, Jordi
    Besse, Benjamin
    CLINICAL LUNG CANCER, 2022, 23 (02) : 87 - 89
  • [35] Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors
    Jiang, Tao
    Bai, Yuchen
    Zhou, Fei
    Li, Wei
    Gao, Guanghui
    Su, Chunxia
    Ren, Shengxiang
    Chen, Xiaoxia
    Zhou, Caicun
    LUNG CANCER, 2019, 130 : 76 - 83
  • [36] Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies
    Tanaka, Tomohiro
    Yoshida, Tatsuya
    Masuda, Ken
    Takeyasu, Yuki
    Shinno, Yuki
    Matsumoto, Yuji
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    RESPIRATORY INVESTIGATION, 2023, 61 (01) : 74 - 81
  • [37] [Cuproptosis-related immune gene signature predicts clinical benefits from anti-PD-1/PD-L1 therapy in non-small-cell lung cancer
    Luo, Linfeng
    Li, Anlin
    Fu, Sha
    Du, Wei
    He, Li-Na
    Zhang, Xuanye
    Wang, Yixing
    Zhou, Yixin
    Yunpeng, Yang
    Li, Zhang
    Hong, Shaodong
    IMMUNOLOGIC RESEARCH, 2023, 71 (02) : 213 - 228
  • [38] [Cuproptosis-related immune gene signature predicts clinical benefits from anti-PD-1/PD-L1 therapy in non-small-cell lung cancer
    Linfeng Luo
    Anlin Li
    Sha Fu
    Wei Du
    Li-Na He
    Xuanye Zhang
    Yixing Wang
    Yixin Zhou
    Yang Yunpeng
    Zhang Li
    Shaodong Hong
    Immunologic Research, 2023, 71 : 213 - 228
  • [39] Modifying factors of PD-L1 expression on tumor cells in advanced non-small-cell lung cancer
    Aviles-Salas, Alejandro
    Flores-Estrada, Diana
    Lara-Mejia, Luis
    Catalan, Rodrigo
    Cruz-Rico, Graciela
    Orozco-Morales, Mario
    Heredia, David
    Bolano-Guerra, Laura
    Soberanis-Pina, Pamela Denisse
    Varela-Santoyo, Edgar
    Cardona, Andres F.
    Arrieta, Oscar
    THORACIC CANCER, 2022, 13 (23) : 3362 - 3373
  • [40] Prognostic implication of PD-L1 polymorphisms in non-small cell lung cancer treated with radiotherapy
    Kang, Min Kyu
    Lee, Shin Yup
    Choi, Jin Eun
    Do, Sook Kyung
    Cho, Moon-June
    Kim, Jun-Sang
    Park, Jae Yong
    CANCER MEDICINE, 2021, 10 (22): : 8071 - 8078
12345